Kaken Pharmaceutical has revealed the phase 3 results that supported its recent marketing application for serabelisib in ...
Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, has been awarded an Advanced Research Projects Agency for Health (ARPA-H) contract to develop advanced ...
Vasomune Therapeutics, Inc. ("Vasomune"), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that Dr. Harold Kim, Chief Scientific Officer, will ...
NEWPORT NEWS, Va. and LONDON, July 22, 2026 /PRNewswire/ -- ivWatch, the IV safety company, today announced that its ...
A $100 million global trial will investigate whether adding a metabolism-targeting therapy to multidomain lifestyle intervention further reduces the risk of cognitive decline in older adults at risk ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
Opportunities span cell therapy, transplant expansion, standardized collection, digital traceability, AI-enabled workflows, ...
Cancer therapy has dramatically changed over the past many decades, not only in efficacy but also complexity, with targeted ...
A new study by investigators from Mass General Brigham finds that nearly 1 in 3 U.S. adults without heart disease—and almost ...
Medtronic (NYSE:MDT) has completed its $550 million acquisition of Scientia Vascular. The deal brings specialized guidewires and catheters for cerebral vasculature into Medtronic's neurovascular ...
MedPage Today on MSN
Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration
Stable vision and retinal anatomy for up to 5 years, no supplemental therapy for up to 2 y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results